CD44

CD44 molecule (Indian blood group), the group of CD molecules|Proteoglycans|Blood group antigens

Basic information

Region (hg38): 11:35138882-35232402

Previous symbols: [ "MIC4", "MDU2", "MDU3" ]

Links

ENSG00000026508NCBI:960OMIM:107269HGNC:1681Uniprot:P16070AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Blood group, IndianBGHematologicVariants associated with a blood group may be important in specific situations (eg, related to transfusion)Hematologic1146277; 8636151

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the CD44 gene.

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the CD44 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
6
clinvar
7
clinvar
13
missense
30
clinvar
3
clinvar
5
clinvar
38
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
2
1
3
non coding
1
clinvar
3
clinvar
4
Total 0 0 31 12 12

Variants in CD44

This is a list of pathogenic ClinVar variants found in the CD44 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
11-35139361-G-A not specified Uncertain significance (Aug 04, 2023)2615985
11-35150575-G-A Calcium oxalate urolithiasis association (Mar 01, 2014)126867
11-35153498-T-C Calcium oxalate urolithiasis association (Mar 01, 2014)126868
11-35158104-G-A Calcium oxalate urolithiasis association (Mar 01, 2014)126869
11-35163005-A-T Calcium oxalate urolithiasis association (Mar 01, 2014)126870
11-35166644-G-A Calcium oxalate urolithiasis association (Mar 01, 2014)126871
11-35169898-C-G Calcium oxalate urolithiasis association (Mar 01, 2014)126872
11-35170667-G-A Calcium oxalate urolithiasis association (Mar 01, 2014)126873
11-35170732-A-G Calcium oxalate urolithiasis association (Mar 01, 2014)126874
11-35171082-C-T Calcium oxalate urolithiasis association (Mar 01, 2014)126875
11-35176617-A-C not specified Uncertain significance (Jan 24, 2023)2478814
11-35176643-C-T not specified Uncertain significance (Mar 17, 2023)2526453
11-35176644-G-A INDIAN BLOOD GROUP SYSTEM POLYMORPHISM Benign (Jan 15, 1994)599021
11-35176654-C-T Likely benign (May 25, 2018)756343
11-35176696-G-T not specified Uncertain significance (May 08, 2024)3264842
11-35179369-G-A Calcium oxalate urolithiasis association (Mar 01, 2014)126876
11-35180295-C-T CD44-related disorder Benign (Oct 21, 2019)3059200
11-35180309-G-A not specified Uncertain significance (May 12, 2024)3264843
11-35180369-A-G not specified Uncertain significance (Jan 04, 2024)3140596
11-35180385-C-T Likely benign (May 24, 2018)748251
11-35180414-T-C Benign (Jul 23, 2018)709993
11-35189836-T-G Likely benign (Jul 21, 2018)756739
11-35189886-C-T not specified Uncertain significance (Sep 27, 2021)2216609
11-35189887-G-A CD44-related disorder Benign (Jul 23, 2018)745899
11-35189914-C-A not specified Uncertain significance (Feb 05, 2024)3140597

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
CD44protein_codingprotein_codingENST00000428726 1893533
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
2.45e-71.0012563701101257470.000437
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.8423584060.8820.00002064882
Missense in Polyphen84116.280.722411369
Synonymous-0.02751451451.000.000007751399
Loss of Function3.251840.20.4480.00000206461

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.001220.00122
Ashkenazi Jewish0.000.00
East Asian0.002290.00229
Finnish0.00004620.0000462
European (Non-Finnish)0.0001950.000193
Middle Eastern0.002290.00229
South Asian0.0001630.000163
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collagens, and matrix metalloproteinases (MMPs). Adhesion with HA plays an important role in cell migration, tumor growth and progression. In cancer cells, may play an important role in invadopodia formation. Also involved in lymphocyte activation, recirculation and homing, and in hematopoiesis. Altered expression or dysfunction causes numerous pathogenic phenotypes. Great protein heterogeneity due to numerous alternative splicing and post-translational modification events. Receptor for LGALS9; the interaction enhances binding of SMAD3 to the FOXP3 promoter, leading to up-regulation of FOXP3 expression and increased induced regulatory T (iTreg) cell stability and suppressive function (By similarity). {ECO:0000250|UniProtKB:P15379, ECO:0000269|PubMed:16541107}.;
Pathway
ECM-receptor interaction - Homo sapiens (human);Shigellosis - Homo sapiens (human);Proteoglycans in cancer - Homo sapiens (human);MicroRNAs in cancer - Homo sapiens (human);Hematopoietic cell lineage - Homo sapiens (human);Epstein-Barr virus infection - Homo sapiens (human);Hepatitis C and Hepatocellular Carcinoma;Wnt Signaling Pathway and Pluripotency;Senescence and Autophagy in Cancer;Neutrophil degranulation;Hyaluronan uptake and degradation;Hyaluronan metabolism;Metabolism of carbohydrates;Cytokine Signaling in Immune system;Integrin cell surface interactions;Glycosaminoglycan metabolism;Extracellular matrix organization;Innate Immune System;Immune System;Metabolism;Integrin;TGF_beta_Receptor;Cell surface interactions at the vascular wall;Hemostasis;Degradation of the extracellular matrix;Interferon gamma signaling;Wnt Canonical;Osteopontin-mediated events;Interferon Signaling;Wnt Mammals (Consensus)

Recessive Scores

pRec
0.949

Intolerance Scores

loftool
0.890
rvis_EVS
0.23
rvis_percentile_EVS
68.52

Haploinsufficiency Scores

pHI
0.161
hipred
Y
hipred_score
0.598
ghis
0.473

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.492

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Cd44
Phenotype
pigmentation phenotype; neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; renal/urinary system phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; digestive/alimentary phenotype; muscle phenotype; limbs/digits/tail phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); endocrine/exocrine gland phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype;

Gene ontology

Biological process
inflammatory response;cell adhesion;cell-matrix adhesion;extracellular matrix disassembly;extracellular matrix organization;hyaluronan catabolic process;positive regulation of peptidyl-serine phosphorylation;positive regulation of heterotypic cell-cell adhesion;negative regulation of apoptotic process;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;neutrophil degranulation;negative regulation of DNA damage response, signal transduction by p53 class mediator;wound healing, spreading of cells;cellular response to fibroblast growth factor stimulus;positive regulation of peptidyl-tyrosine phosphorylation;leukocyte migration;cartilage development;interferon-gamma-mediated signaling pathway;positive regulation of ERK1 and ERK2 cascade;monocyte aggregation;cell-cell adhesion;positive regulation of monocyte aggregation;negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;regulation of lamellipodium morphogenesis
Cellular component
Golgi apparatus;cytosol;plasma membrane;integral component of plasma membrane;microvillus;focal adhesion;cell surface;basolateral plasma membrane;apical plasma membrane;secretory granule membrane;lamellipodium membrane;macrophage migration inhibitory factor receptor complex;cell projection;extracellular exosome
Molecular function
transmembrane signaling receptor activity;cytokine receptor activity;protein binding;collagen binding;hyaluronic acid binding